News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rib-X Pharmaceuticals, Inc. Reports Preclinical Studies at ICAAC With Novel Classes of RX-04 Antibiotic Compounds Demonstrating Potent and Rapid Efficacy in a S. pneumoniae Lung Model of Infection and Activity Against a Diverse Spectrum of Biodefense Pathogens


9/12/2012 10:17:01 AM

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced today the presentation of five posters featuring completely new antibiotic compounds from the company’s RX-04 program at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 9-12, 2012 in San Francisco, CA. The reported data from multiple preclinical studies emphasized the potent, broad spectrum activity of RX-04 compounds, including at single, low doses. A study conducted in a Streptococcus pneumoniae lung infection model established the potential for this class of compounds to address respiratory pathogens. Additionally, studies demonstrated the unique activity of these novel antibiotics across a diverse array of bacterial pathogens, including against carbapenem- and colistin-resistant strains of Klebsiella pneumoniae and five major biodefense pathogens.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES